ATE497781T1 - Impfstoffe auf mannoproteinfreier beta-glucan- basis - Google Patents
Impfstoffe auf mannoproteinfreier beta-glucan- basisInfo
- Publication number
- ATE497781T1 ATE497781T1 AT07075796T AT07075796T ATE497781T1 AT E497781 T1 ATE497781 T1 AT E497781T1 AT 07075796 T AT07075796 T AT 07075796T AT 07075796 T AT07075796 T AT 07075796T AT E497781 T1 ATE497781 T1 AT E497781T1
- Authority
- AT
- Austria
- Prior art keywords
- glucan
- antibodies
- protective
- presented
- mannoprotein
- Prior art date
Links
- SPMCUTIDVYCGCK-IIIGWGBSSA-N (2s,3r,4s,5r,6r)-2-[(2r,3r,4r,5s)-3,5-dihydroxy-2-(hydroxymethyl)oxan-4-yl]oxy-4-[(2s,3r,5s,6r)-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-3,5-diol Chemical compound O[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)OC[C@@H]2O)O)O[C@H](CO)[C@H]1O SPMCUTIDVYCGCK-IIIGWGBSSA-N 0.000 title 1
- 229920002498 Beta-glucan Polymers 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 229920001503 Glucan Polymers 0.000 abstract 7
- 230000001681 protective effect Effects 0.000 abstract 4
- 241000222122 Candida albicans Species 0.000 abstract 1
- 206010017533 Fungal infection Diseases 0.000 abstract 1
- 208000031888 Mycoses Diseases 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000003641 microbiacidal effect Effects 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0211118.5A GB0211118D0 (en) | 2002-05-15 | 2002-05-15 | Vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE497781T1 true ATE497781T1 (de) | 2011-02-15 |
Family
ID=9936711
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07075796T ATE497781T1 (de) | 2002-05-15 | 2003-05-15 | Impfstoffe auf mannoproteinfreier beta-glucan- basis |
| AT03730424T ATE395080T1 (de) | 2002-05-15 | 2003-05-15 | Impfstoffe gegen pilzen aus beta-glucan |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03730424T ATE395080T1 (de) | 2002-05-15 | 2003-05-15 | Impfstoffe gegen pilzen aus beta-glucan |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US20050208079A1 (enExample) |
| EP (2) | EP1891970B1 (enExample) |
| JP (3) | JP5110767B2 (enExample) |
| AT (2) | ATE497781T1 (enExample) |
| AU (1) | AU2003241104A1 (enExample) |
| CA (2) | CA2485847C (enExample) |
| CY (1) | CY1108234T1 (enExample) |
| DE (2) | DE60320979D1 (enExample) |
| DK (1) | DK1506009T3 (enExample) |
| ES (1) | ES2306871T3 (enExample) |
| GB (1) | GB0211118D0 (enExample) |
| PT (1) | PT1506009E (enExample) |
| SI (1) | SI1506009T1 (enExample) |
| WO (1) | WO2003097091A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507724B2 (en) * | 2001-01-16 | 2009-03-24 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| US7906492B2 (en) | 2001-01-16 | 2011-03-15 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| US8071552B2 (en) * | 2004-04-05 | 2011-12-06 | Universite Bordeaux 2 | Peptides and peptidomimetics binding to CD23 |
| GB0420466D0 (en) * | 2004-09-14 | 2004-10-20 | Cassone Antonio | Anti-glucan antibodies |
| PL2878307T3 (pl) | 2005-06-27 | 2020-01-31 | Glaxosmithkline Biologicals S.A. | Kompozycja immunogenna |
| WO2007084661A2 (en) * | 2006-01-17 | 2007-07-26 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| US8323644B2 (en) * | 2006-01-17 | 2012-12-04 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| US20090053221A1 (en) * | 2006-01-17 | 2009-02-26 | Cheung Nai-Kong V | Immune response enhancing glucan |
| WO2007127668A2 (en) * | 2006-04-26 | 2007-11-08 | Wyeth | Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations |
| WO2009134891A2 (en) * | 2008-04-29 | 2009-11-05 | Immunexcite, Inc. | Immunomodulating compositions and methods of use thereof |
| US9457047B2 (en) | 2006-11-06 | 2016-10-04 | Whitehead Institute | Immunomodulating compositions and methods of use thereof |
| ES2397186T3 (es) * | 2006-11-06 | 2013-03-05 | Whitehead Institute | Composiciones inmunomoduladoras y métodos para su uso |
| AU2013203785B2 (en) * | 2006-11-06 | 2016-11-17 | Immunexcite, Inc. | Immunomodulating compositions and methods of use thereof |
| JP4687644B2 (ja) | 2006-12-22 | 2011-05-25 | 富士ゼロックス株式会社 | 画像処理装置、画像読取装置及び画像形成装置 |
| US9439954B2 (en) | 2007-11-26 | 2016-09-13 | Glaxosmithkline Biologicals Sa | Conjugated beta-1,3-linked glucans |
| CA2706617A1 (en) † | 2007-11-26 | 2009-06-25 | Novartis Ag | Adjuvanted glucans |
| US20110236489A1 (en) | 2008-09-18 | 2011-09-29 | Novartis Ag | Vaccine adjuvant combinations |
| NL1036661C2 (en) | 2009-03-04 | 2010-09-07 | Serrix B V | Anti-fungal compounds & compositions. |
| JP2012520289A (ja) * | 2009-03-10 | 2012-09-06 | パルメッド テバ リミテッド | 新規なコプリヌス・コマトゥスおよびトレメッラ・メセンテリカキノコ菌株、それらの生産物および抽出物、ならびにそれらを含む組成物 |
| CN102740882A (zh) | 2009-08-27 | 2012-10-17 | 诺华有限公司 | 含有铝、寡核苷酸和聚阳离子的佐剂 |
| ES2443952T3 (es) | 2009-09-02 | 2014-02-21 | Novartis Ag | Composiciones inmunógenas que incluyen moduladores de la actividad de TLR |
| WO2011035205A2 (en) | 2009-09-18 | 2011-03-24 | Calmune Corporation | Antibodies against candida, collections thereof and methods of use |
| EA201291091A1 (ru) * | 2010-05-14 | 2013-05-30 | Олтек, Инк. | Компоненты клеточной стенки дрожжей и их обнаружение |
| CN105999275A (zh) | 2010-09-01 | 2016-10-12 | 诺华有限公司 | 免疫增强剂吸附不溶性金属离子 |
| US9618508B2 (en) | 2010-12-14 | 2017-04-11 | Glaxosmithkline Biologicals Sa | Flow cytometry analysis of materials adsorbed to metal salts |
| US20140112950A1 (en) | 2011-03-02 | 2014-04-24 | Manmohan Singh | Combination vaccines with lower doses of antigen and/or adjuvant |
| US9149541B2 (en) | 2011-07-08 | 2015-10-06 | Novartis Ag | Tyrosine ligation process |
| JP6170932B2 (ja) | 2011-11-07 | 2017-07-26 | ノバルティス アーゲー | ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子 |
| HRP20161354T1 (hr) | 2012-03-07 | 2016-12-02 | Glaxosmithkline Biologicals Sa | Argininske soli agonista tlr7 |
| JP2015510872A (ja) | 2012-03-07 | 2015-04-13 | ノバルティス アーゲー | Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤 |
| US9375471B2 (en) | 2012-03-08 | 2016-06-28 | Glaxosmithkline Biologicals Sa | Adjuvanted formulations of booster vaccines |
| US10092646B2 (en) * | 2012-04-30 | 2018-10-09 | Biothera, Inc. | Compositions and methods for beta-glucan immunotherapy |
| TR201807340T4 (tr) | 2013-02-01 | 2018-06-21 | Glaxosmithkline Biologicals Sa | Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi. |
| CN103083663B (zh) * | 2013-02-04 | 2014-12-10 | 江苏省农业科学院 | 一种免疫增强剂、灭活疫苗及其制备方法 |
| US20160017062A1 (en) | 2013-03-12 | 2016-01-21 | Wellstat Vaccines, Llc | Antibodies targeted to fungal cell wall polysaccharides |
| CN105593238B (zh) | 2013-07-11 | 2020-09-08 | 诺华股份有限公司 | 使用微生物转谷氨酰胺酶进行赖氨酸特异性化学酶法蛋白质修饰 |
| US9885726B2 (en) * | 2013-12-05 | 2018-02-06 | Biothera, Inc. | β-glucan assay methods |
| ES2857557T3 (es) * | 2015-01-26 | 2021-09-29 | Kaleido Biosciences Inc | Compuestos terapéuticos de glicano y métodos relacionados de los mismos |
| CN104771498A (zh) * | 2015-03-13 | 2015-07-15 | 臧海阳 | 一种治疗热毒蕴结型痄腮的中药组合物 |
| US11815435B2 (en) | 2017-02-24 | 2023-11-14 | Hibercell, Inc. | Beta glucan immunopharmacodynamics |
| KR102795692B1 (ko) * | 2018-01-19 | 2025-04-16 | 밀테니 비오텍 비.브이. & 씨오. 케이지 | 키메라 항원 수용체를 발현하는 조절 t 세포 |
| US11701417B2 (en) * | 2019-03-27 | 2023-07-18 | West Virginia University | Vaccine formulation to protect against pertussis |
| WO2023002252A1 (en) | 2021-07-21 | 2023-01-26 | Bioatlantis Limited | Composition comprising beta-glucans and alpha-fucans for improving gut health and animal performance and methods of making the same |
| AU2023225283A1 (en) | 2022-02-28 | 2024-08-22 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN. |
| EP4486387A1 (en) | 2022-02-28 | 2025-01-08 | Tridem Bioscience GmbH & Co KG | A conjugate consisting of or comprising at least a ss-glucan or a mannan |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE466289B (sv) * | 1984-09-19 | 1992-01-27 | James Hoffman | Makrofagstimulerande komposition jaemte foerfarande foer dess framstaellning |
| JPS6383012A (ja) * | 1986-09-26 | 1988-04-13 | Nonogawa Shoji:Kk | 化粧料 |
| JPH05503952A (ja) * | 1989-09-08 | 1993-06-24 | アルファ ベータ テクノロジー，インコーポレイティッド | 可溶性グルカン類の製造方法 |
| EP0471954A3 (en) | 1990-08-13 | 1993-03-03 | American Cyanamid Company | Immunogenic conjugates of nontoxic oligosaccharide derived from bordetella pertussis lipooligosaccharide |
| US5153312A (en) * | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
| ATE280235T1 (de) * | 1993-03-05 | 2004-11-15 | Wyeth Corp | Plasmid zur herstellung von crm-protein und diphtherie-toxin |
| CN1094288A (zh) * | 1993-04-23 | 1994-11-02 | 福建省微生物研究所 | 利用红色诺卡氏菌制造细胞壁骨架粉末的方法 |
| NO300692B1 (no) | 1994-04-29 | 1997-07-07 | Biotec Mackzymal As | Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan |
| US6309642B1 (en) * | 1997-04-28 | 2001-10-30 | The Research And Development Institute, Inc. | Peptides which mimic candida carbohydrate epitopes and their use in a vaccine |
| AUPN166195A0 (en) * | 1995-03-13 | 1995-04-06 | Norvet Research Pty Limited | Process for glucan extraction |
| JPH09309842A (ja) * | 1996-05-20 | 1997-12-02 | Kureha Chem Ind Co Ltd | 新規な生理活性物質、その製造方法及び医薬組成物 |
| AU760669B2 (en) * | 1998-04-28 | 2003-05-22 | Galenica Pharmaceuticals, Inc. | Polysaccharide-antigen conjugates |
| US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
| GB9925559D0 (en) * | 1999-10-28 | 1999-12-29 | Smithkline Beecham Biolog | Novel method |
| JP4230635B2 (ja) | 2000-02-29 | 2009-02-25 | 富士フイルム株式会社 | デジタルカメラ |
-
2002
- 2002-05-15 GB GBGB0211118.5A patent/GB0211118D0/en not_active Ceased
-
2003
- 2003-05-15 DE DE60320979T patent/DE60320979D1/de not_active Expired - Lifetime
- 2003-05-15 CA CA2485847A patent/CA2485847C/en not_active Expired - Fee Related
- 2003-05-15 EP EP07075796A patent/EP1891970B1/en not_active Expired - Lifetime
- 2003-05-15 DE DE60336027T patent/DE60336027D1/de not_active Expired - Lifetime
- 2003-05-15 SI SI200331275T patent/SI1506009T1/sl unknown
- 2003-05-15 PT PT03730424T patent/PT1506009E/pt unknown
- 2003-05-15 US US10/514,483 patent/US20050208079A1/en not_active Abandoned
- 2003-05-15 CA CA2830619A patent/CA2830619A1/en not_active Abandoned
- 2003-05-15 AT AT07075796T patent/ATE497781T1/de not_active IP Right Cessation
- 2003-05-15 ES ES03730424T patent/ES2306871T3/es not_active Expired - Lifetime
- 2003-05-15 WO PCT/IB2003/002460 patent/WO2003097091A2/en not_active Ceased
- 2003-05-15 DK DK03730424T patent/DK1506009T3/da active
- 2003-05-15 AT AT03730424T patent/ATE395080T1/de active
- 2003-05-15 AU AU2003241104A patent/AU2003241104A1/en not_active Abandoned
- 2003-05-15 JP JP2004505087A patent/JP5110767B2/ja not_active Expired - Fee Related
- 2003-05-15 EP EP03730424A patent/EP1506009B1/en not_active Expired - Lifetime
-
2007
- 2007-02-01 US US11/701,250 patent/US7824688B2/en not_active Expired - Fee Related
-
2008
- 2008-07-31 CY CY20081100809T patent/CY1108234T1/el unknown
-
2009
- 2009-12-25 JP JP2009294467A patent/JP2010131017A/ja active Pending
-
2010
- 2010-08-11 US US12/854,248 patent/US8398990B2/en not_active Expired - Fee Related
-
2012
- 2012-07-27 JP JP2012166700A patent/JP5684758B2/ja not_active Expired - Fee Related
-
2013
- 2013-02-26 US US13/777,903 patent/US8679506B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2485847C (en) | 2013-12-31 |
| JP2005535298A (ja) | 2005-11-24 |
| US7824688B2 (en) | 2010-11-02 |
| JP2010131017A (ja) | 2010-06-17 |
| JP2012224636A (ja) | 2012-11-15 |
| CY1108234T1 (el) | 2014-02-12 |
| US20050208079A1 (en) | 2005-09-22 |
| PT1506009E (pt) | 2008-08-14 |
| HK1069125A1 (en) | 2005-05-13 |
| ATE395080T1 (de) | 2008-05-15 |
| US20130171187A1 (en) | 2013-07-04 |
| CA2485847A1 (en) | 2003-11-27 |
| US20110059120A1 (en) | 2011-03-10 |
| DK1506009T3 (da) | 2008-09-01 |
| WO2003097091A3 (en) | 2004-03-04 |
| HK1114335A1 (en) | 2008-10-31 |
| GB0211118D0 (en) | 2002-06-26 |
| AU2003241104A1 (en) | 2003-12-02 |
| EP1891970B1 (en) | 2011-02-09 |
| SI1506009T1 (sl) | 2008-10-31 |
| DE60320979D1 (de) | 2008-06-26 |
| ES2306871T3 (es) | 2008-11-16 |
| EP1506009B1 (en) | 2008-05-14 |
| US8679506B2 (en) | 2014-03-25 |
| WO2003097091A2 (en) | 2003-11-27 |
| CA2830619A1 (en) | 2003-11-27 |
| EP1506009A2 (en) | 2005-02-16 |
| DE60336027D1 (de) | 2011-03-24 |
| JP5684758B2 (ja) | 2015-03-18 |
| US8398990B2 (en) | 2013-03-19 |
| US20070141088A1 (en) | 2007-06-21 |
| EP1891970A1 (en) | 2008-02-27 |
| JP5110767B2 (ja) | 2012-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE497781T1 (de) | Impfstoffe auf mannoproteinfreier beta-glucan- basis | |
| PL377146A1 (pl) | Cytokiny ochronne dla tkanek do ochrony, odnowy i wzmacniania reaktywnych komórek, tkanek i narządów | |
| WO2004108093A3 (en) | Antiseptic compositions, methods and systems | |
| EP2266607A3 (en) | Immunoconjugates for treating cancer | |
| CA2378892A1 (en) | Preserved pharmaceutical formulations | |
| TW200514580A (en) | Adhesive preparations | |
| MXPA03008401A (es) | Combinacion de brimonidina y timolol para uso oftalmico, topico. | |
| WO2005000241A3 (en) | Compositons and methods for topical administration | |
| WO2003045306A3 (en) | Phenoxy amine compounds and compositions for delivering active agents | |
| EP4295917A3 (en) | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy | |
| HK1041209A1 (zh) | 加強藥物療效的成份及方法 | |
| ATE270115T1 (de) | Behandlung einer intrazelluläre infektion | |
| WO2004087098A3 (en) | Preserved ophthalmic compositions | |
| WO2003039592A3 (de) | Zelluläre impfstoffe mit adjuvanzien | |
| WO2003082926A3 (en) | Antimicrobial polymer conjugates | |
| EA200501828A1 (ru) | Тканепротекторные цитокины с увеличенным терапевтическим окном для защиты, восстановления и стимулирования реагирующих клеток, тканей и органов | |
| DK1187611T3 (da) | Oftalmiske histaminholdige sammensætninger og anvendelse deraf | |
| WO2003009859A1 (en) | Immunotherapy for humans | |
| WO2006121522A3 (en) | Implantable sensors and pumps, anti-scarring agents, and therapeutic compositions | |
| WO2004006851A3 (en) | Mycoplasma gallisepticum formulation | |
| AU4747497A (en) | Sordarin derivatives | |
| WO2002055022A3 (en) | Active metabolite of antifungal compound | |
| WO2003000174A3 (en) | Compositions and methods for intracellular delivery | |
| WO2003077885A3 (en) | Free-base formulations of local anesthetics | |
| HK40120055A (zh) | 包含靶向claudin18.2的抗体-药物偶联物的制剂及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |